I am still not sure what more you want Latkin to do to move the FDA and Jubilant along?
Yes he made a new CEO mistake in assuming a deal would be made quickly, his bad, but that does not make him a liar. If I were him at this point I would stall Jubilant and up the deal's price on excellent trial results.
The FDA is a slow iterative process and according to Smith they have outside consultants assisting them. Slow, steady, progress is galling for many, but its progress.
The science is also progressing.
I think targeted therapeutics is worth billions so I will continue to buy. My average PPS has dropped considerably.
Why not average down?